Second line treatment of non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 385-387, 2015.
Article
en Zh
| WPRIM
| ID: wpr-467412
Biblioteca responsable:
WPRO
ABSTRACT
The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors(TKIs)erlotinib and gefitinib are standard second-line therapies for non-small cell lung cancer. For patients without the EGFR mutation,more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard second-line treatment is an trend of exploration,but without promising results nowadays. Crizotinib,targeting at anaplastic lymphoma kinase,has been shown excellent efficacy for second-line therapy in non-small cell lung cancer.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Año:
2015
Tipo del documento:
Article